EULAR points to consider for the management of difficult-to-treat-rheumatoid arthritis (Part 9)
Allow me to present the concluding statements regarding this topic about the
management of difficult to treat rheumatoid arthritis (D2T RA).
The European Alliance of Associations for Rheumatology (EULAR) formulated points to consider when treating D2T RA to serve as a clinical roadmap to support healthcare professionals and patients to deliver holistic management and more personalised pharmacological and non-pharmacological therapeutic strategies.
The guidelines or points to consider is based on high-quality evidence was scarce.
This is the reason for the need to conduct research or to have a guide for researchers.
We are glad that the treatment options for D2T RA have become wider with availability of biological and targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs).
The key takeaway is to follow or to ensure the compliance of the patients when it comes to the treatment modalities. There are several treatments available but sub compliance or non-compliance means that the patients of D2T RA will have harder time recovering or be in remission.
Research on this topic has contributed immensely to the improved outcomes the majority of patients with RA.
It is acknowledged that D2T RA patients provide a unique challenge in clinical practice.
Thus, the reason for the formulation of the points to consider for this specific patient population.